Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia
Status:
Recruiting
Trial end date:
2023-03-20
Target enrollment:
Participant gender:
Summary
The study will include 60 patients after cardiac surgery. The first group will include 30
patients who will use the drug Neodolpasse manufactured by Fresenius Kabi, which is a fixed
combination of 30 mg of orphenadrine and 75 mg of diclofenac; the second group will consist
of 30 patients who will use patient-controlled morphine analgesia (РСА) in the form of
monotherapy.